WO2016178092A3 - C-3 novel triterpenone with c-28 reverse amide derivatives as hiv inhibitors - Google Patents

C-3 novel triterpenone with c-28 reverse amide derivatives as hiv inhibitors Download PDF

Info

Publication number
WO2016178092A3
WO2016178092A3 PCT/IB2016/000811 IB2016000811W WO2016178092A3 WO 2016178092 A3 WO2016178092 A3 WO 2016178092A3 IB 2016000811 W IB2016000811 W IB 2016000811W WO 2016178092 A3 WO2016178092 A3 WO 2016178092A3
Authority
WO
WIPO (PCT)
Prior art keywords
amide derivatives
reverse amide
hiv inhibitors
triterpenone
novel
Prior art date
Application number
PCT/IB2016/000811
Other languages
French (fr)
Other versions
WO2016178092A8 (en
WO2016178092A2 (en
Inventor
Bandi Parthasaradhi Reddy
Gazula Levi DAVID KRUPADANAM
Adulla PANDURANGA REDDY
Kasireddy BHASKAR REDDY
Lanka Vl Subrahmanyam
Kura Rathnakar Reddy
Original Assignee
Hetero Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57153504&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2016178092(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to MA40886A priority Critical patent/MA40886B1/en
Priority to SG11201706189PA priority patent/SG11201706189PA/en
Priority to KR1020177024961A priority patent/KR20170110143A/en
Application filed by Hetero Research Foundation filed Critical Hetero Research Foundation
Priority to EA201791807A priority patent/EA033264B1/en
Priority to EP16784277.2A priority patent/EP3256483B1/en
Priority to CU2017000102A priority patent/CU24476B1/en
Priority to AU2016258274A priority patent/AU2016258274B2/en
Priority to BR112017017109A priority patent/BR112017017109A2/en
Priority to MX2017010297A priority patent/MX2017010297A/en
Priority to CA2975359A priority patent/CA2975359A1/en
Priority to US15/549,678 priority patent/US10533035B2/en
Priority to DK16784277.2T priority patent/DK3256483T3/en
Priority to ES16784277T priority patent/ES2780649T3/en
Priority to JP2017559931A priority patent/JP2018505216A/en
Priority to CN201680009544.1A priority patent/CN107428797A/en
Publication of WO2016178092A2 publication Critical patent/WO2016178092A2/en
Publication of WO2016178092A3 publication Critical patent/WO2016178092A3/en
Priority to ZA2017/05253A priority patent/ZA201705253B/en
Priority to IL253844A priority patent/IL253844A0/en
Priority to PH12017550077A priority patent/PH12017550077A1/en
Priority to CONC2017/0008765A priority patent/CO2017008765A2/en
Publication of WO2016178092A8 publication Critical patent/WO2016178092A8/en
Priority to US16/688,400 priority patent/US11034718B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formula (I) The invention relates to C-3 novel triterpenone with C-28 reverse amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.
PCT/IB2016/000811 2015-02-09 2016-02-09 C-3 novel triterpenone with c-28 reverse amide derivatives as hiv inhibitors WO2016178092A2 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
MA40886A MA40886B1 (en) 2015-02-09 2016-02-08 Novel c-3 triterpenone with c-28 reverse amide derivatives as hiv inhibitors
KR1020177024961A KR20170110143A (en) 2015-02-09 2016-02-09 C-3 New Tritterpenone with C-17 Reverse Amide Derivatives as HIV Inhibitors
DK16784277.2T DK3256483T3 (en) 2015-02-09 2016-02-09 HIS UNKNOWN C-3-TRITERPENON WITH REVERSE C-17 AMIDE DERIVATIVES AS ANTI-HIV INHIBITORS
US15/549,678 US10533035B2 (en) 2015-02-09 2016-02-09 C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors
EA201791807A EA033264B1 (en) 2015-02-09 2016-02-09 C-3 novel triterpenone with c-17 reverse amide derivatives as hiv inhibitors
EP16784277.2A EP3256483B1 (en) 2015-02-09 2016-02-09 Novel c-3 triterpenone with c-17 reverse amide derivatives as hiv inhibitors
CU2017000102A CU24476B1 (en) 2015-02-09 2016-02-09 NEW TRITERPENONE C-3 WITH C-17 INVERSE AMIDE DERIVATIVES AS HIV INHIBITORS
AU2016258274A AU2016258274B2 (en) 2015-02-09 2016-02-09 C-3 novel triterpenone with c-17 reverse amide derivatives as hiv inhibitors
BR112017017109A BR112017017109A2 (en) 2015-02-09 2016-02-09 new c-3 triterpenone with c-28 reverse starch derivatives as hiv inhibitors
MX2017010297A MX2017010297A (en) 2015-02-09 2016-02-09 C-3 novel triterpenone with c-28 reverse amide derivatives as hiv inhibitors.
ES16784277T ES2780649T3 (en) 2015-02-09 2016-02-09 New C-3 triterpenone with C-17 reverse amide derivatives as HIV inhibitors
SG11201706189PA SG11201706189PA (en) 2015-02-09 2016-02-09 C-3 novel triterpenone with c-17 reverse amide derivatives as hiv inhibitors
CN201680009544.1A CN107428797A (en) 2015-02-09 2016-02-09 The new triterpene ketenes of C 3 with 28 reverse amide derivatives of C as hiv inhibitor
CA2975359A CA2975359A1 (en) 2015-02-09 2016-02-09 C-3 novel triterpenone with c-28 reverse amide derivatives as hiv inhibitors
JP2017559931A JP2018505216A (en) 2015-02-09 2016-02-09 C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors
ZA2017/05253A ZA201705253B (en) 2015-02-09 2017-08-03 C-3 novel triterpenone with c-17 reverse amide derivatives as hiv inhibitors
IL253844A IL253844A0 (en) 2015-02-09 2017-08-06 C-3 novel triterpenone with c-17 reverse amide derivatives as hiv inhibitors
PH12017550077A PH12017550077A1 (en) 2015-02-09 2017-08-08 C-3 novel triterpenone with c-17 reverse amide derivatives as hiv inhibitors
CONC2017/0008765A CO2017008765A2 (en) 2015-02-09 2017-08-28 New triterpenone c-3 with reverse amide derivatives c-17 as hiv inhibitors
US16/688,400 US11034718B2 (en) 2015-02-09 2019-11-19 C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN623/CHE/2015 2015-02-09
IN623/CHR/2015 2015-02-09
IN623CH2015 2015-02-09

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/549,678 A-371-Of-International US10533035B2 (en) 2015-02-09 2016-02-09 C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors
US16/688,400 Division US11034718B2 (en) 2015-02-09 2019-11-19 C-3 novel triterpenone with C-17 reverse amide derivatives as HIV inhibitors

Publications (3)

Publication Number Publication Date
WO2016178092A2 WO2016178092A2 (en) 2016-11-10
WO2016178092A3 true WO2016178092A3 (en) 2017-01-05
WO2016178092A8 WO2016178092A8 (en) 2017-09-21

Family

ID=57153504

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/000811 WO2016178092A2 (en) 2015-02-09 2016-02-09 C-3 novel triterpenone with c-28 reverse amide derivatives as hiv inhibitors

Country Status (22)

Country Link
US (3) US10533035B2 (en)
EP (1) EP3256483B1 (en)
JP (1) JP2018505216A (en)
KR (1) KR20170110143A (en)
CN (1) CN107428797A (en)
AU (1) AU2016258274B2 (en)
BR (1) BR112017017109A2 (en)
CA (1) CA2975359A1 (en)
CL (1) CL2017002034A1 (en)
CO (1) CO2017008765A2 (en)
CU (1) CU24476B1 (en)
DK (1) DK3256483T3 (en)
EA (1) EA033264B1 (en)
ES (1) ES2780649T3 (en)
IL (1) IL253844A0 (en)
MA (1) MA40886B1 (en)
MX (1) MX2017010297A (en)
PE (1) PE20171433A1 (en)
PH (1) PH12017550077A1 (en)
SG (1) SG11201706189PA (en)
WO (1) WO2016178092A2 (en)
ZA (1) ZA201705253B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
MA40886B1 (en) 2015-02-09 2020-03-31 Hetero Research Foundation Novel c-3 triterpenone with c-28 reverse amide derivatives as hiv inhibitors
WO2016147099A2 (en) * 2015-03-16 2016-09-22 Hetero Research Foundation C-3 novel triterpenone with c-28 amide derivatives as hiv inhibitors
AR107512A1 (en) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD TRITERPENOIDS MODIFIED IN C-3 AND C-17 AS HIV-1 INHIBITORS
WO2018029604A1 (en) * 2016-08-08 2018-02-15 Hetero Labs Limited C-3 novel triterpenone with c-17 reverse amide derivatives as hiv inhibitors
WO2019150300A1 (en) 2018-02-02 2019-08-08 Glaxosmithkline Intellectual Property (No.2) Limited Crystalline forms of 4-(((3ar,5ar,5br,7ar,9s,11ar,11br,13as)-3a-((r)-2-((4-chlorobenzyl)(2-(dimethylamino)ethyl)amino)-1-hydroxyethyl)-1-isopropyl-5a,5b,8,8,11a-pentamethyl-2-oxo-3,3a,4,5,5a,5b,6,7,7a,8,9,10,11,11a,11b,12,13,13a-octadecahydro-2h-cyclopenta[a]chrysen-9-yl)oxy)-2,2-dimethyl-4-oxobutanoic acid
CN109705189B (en) * 2018-12-29 2020-06-05 中国医学科学院药用植物研究所 Triterpene derivative with structure shown in formula I, preparation method and application thereof
US20220144882A1 (en) * 2019-02-11 2022-05-12 Hetero Labs Limited Novel triterpenone derivatives as hiv inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057420A2 (en) * 2006-11-03 2008-05-15 Panacos Pharmaceuticals, Inc. Extended triterpene derivatives
WO2009082819A1 (en) * 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel lupane derivatives

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58152815A (en) 1982-03-05 1983-09-10 Tamio Nishimura Virucide
WO1995002071A1 (en) 1993-07-09 1995-01-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Selection and use of antiviral peptides
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
WO1998046238A1 (en) 1997-04-15 1998-10-22 Medichem Research, Inc. Biflavinoids and derivatives thereof as antiviral agents, alone or in combination with at least one known antiviral agent
HUP9701080A3 (en) 1997-06-23 1999-05-28 Gene Res Lab Inc New York N Pharmaceutical composition containing a compound of antiviral activity and a hydroximic acid ester derivative
US6670345B1 (en) 1997-09-30 2003-12-30 Dabur Research Foundation Betulinic acid derivatives for inhabiting cancer growth and process for the manufacture of betulinic acid
US6427248B1 (en) 1997-10-09 2002-08-06 David M. Albert Grip-enhancing glove
AU766599B2 (en) 1998-11-18 2003-10-16 Dabur Pharma Ltd. Novel betulinic acid derivatives, processes for preparing such derivatives and its use as cancer growth inhibitors
WO2001007646A2 (en) 1999-07-21 2001-02-01 Martin Heinkelein Method for quantization of the antiviral effect of antiviral active principles
DE69917684T2 (en) 1999-09-09 2005-07-21 Dabur Research Foundation, Sahibabad ANALYTICAL ACIDIC ACID DERIVATIVES, METHOD OF PREPARING SUCH DERIVATIVES, AND THEIR USE IN THE TREATMENT OF TUMOR-ASSOCIATED ANGIOGENESIS
WO2002091858A1 (en) 2001-05-11 2002-11-21 University Of Ottawa Anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods
WO2003037908A1 (en) 2001-10-31 2003-05-08 Ribapharm Inc. Antiviral combination therapy and compositions
SI1594885T1 (en) 2003-02-11 2009-06-30 Novelix Pharmaceuticals Inc Medicament for inhibiting tumour growth
US7026305B2 (en) 2003-04-14 2006-04-11 Meharry Medical College Anti-HIV agents with dual sites of action
US20050239748A1 (en) 2004-03-17 2005-10-27 Panacos Pharmaceuticals, Inc. Pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
WO2006046593A1 (en) 2004-10-27 2006-05-04 Daiichi Sankyo Company, Limited Benzene compound having 2 or more substituents
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
EP1869063A2 (en) 2005-03-29 2007-12-26 Regents Of The University Of Minnesota Methods of manufacturing bioactive 3-esters of betulinic aldehyde and betulinic acid
CN101287744A (en) 2005-06-22 2008-10-15 美瑞德生物工程公司 Antiviral compounds
WO2007002411A1 (en) 2005-06-22 2007-01-04 Myriad Genetics, Inc. Antiviral compounds
CN100475835C (en) 2006-05-12 2009-04-08 中国药科大学 23-Hydroxyl betulinic acid kind derivant and preparing process, preparation and use thereof
FI121468B (en) 2006-06-07 2010-11-30 Valtion Teknillinen Compounds derived from betulin as antimicrobial agents
FI20065389A (en) 2006-06-07 2007-12-31 Valtion Teknillinen Betulin derived compounds as an inhibitor for eating pests
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
US20110152229A1 (en) 2006-11-22 2011-06-23 Duke University Betulinic acid derivatives as anti-hiv agents
WO2008091532A1 (en) 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
US8269026B2 (en) 2008-01-03 2012-09-18 Vertex Pharmaceuticals Incorporated Lupane derivatives useful for treating HIV
EP2240504A1 (en) 2008-01-03 2010-10-20 Virochem Pharma Inc. Novel c-21-keto lupane derivatives preparation and use thereof
JP2011511812A (en) 2008-02-14 2011-04-14 バイロケム ファーマ インコーポレイテッド Novel 17β lupine derivative
US20120101098A1 (en) 2009-05-15 2012-04-26 Kuo-Hsiung Lee 3,28-disubstituted betulinic acid derivatives as anti-hiv agents
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
US8802727B2 (en) 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
BR112012019762A2 (en) 2010-02-11 2016-02-23 Glaxosmithkline Llc compound, composition, and method for treating a disease.
CA2801487C (en) 2010-06-04 2017-12-05 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
US8802661B2 (en) 2010-06-04 2014-08-12 Bristol-Myers Squibb Company C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors
US20140221328A1 (en) 2011-01-10 2014-08-07 Bandi Parthasaradhi Reddy Pharmaceutically acceptable salts of novel betulinic acid derivatives
WO2013001144A1 (en) 2011-06-30 2013-01-03 Nokia Corporation Method and apparatus for face tracking utilizing integral gradient projections
WO2013020245A1 (en) 2011-08-08 2013-02-14 Glaxosmithkline Llc Carbonyl derivatives of betulin
WO2013091144A1 (en) 2011-12-21 2013-06-27 Glaxosmithkline Llc Propenoate derivatives of betulin
AU2012352129B2 (en) 2011-12-14 2016-02-04 Glaxosmithkline Llc Propenoate derivatives of betulin
JO3387B1 (en) 2011-12-16 2019-03-13 Glaxosmithkline Llc Derivatives of betulin
CN103242413B (en) 2012-02-08 2015-08-26 江西青峰药业有限公司 Lupane triterpene system's derivative and pharmaceutical use thereof
US20150119373A1 (en) 2012-04-24 2015-04-30 Hetero Research Foundation Novel betulinic acid derivatives as hiv inhibitors
MX2015007563A (en) 2012-12-14 2015-10-14 Glaxosmithkline Llc Pharmaceutical compositions.
US9637516B2 (en) 2012-12-31 2017-05-02 Hetero Research Foundation Betulinic acid proline derivatives as HIV inhibitors
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
WO2015198263A2 (en) 2014-06-26 2015-12-30 Hetero Research Foundation Novel betulinic proline substituted derivatives as hiv inhibitors
MA40886B1 (en) 2015-02-09 2020-03-31 Hetero Research Foundation Novel c-3 triterpenone with c-28 reverse amide derivatives as hiv inhibitors
WO2016147099A2 (en) 2015-03-16 2016-09-22 Hetero Research Foundation C-3 novel triterpenone with c-28 amide derivatives as hiv inhibitors
WO2017017630A1 (en) 2015-07-28 2017-02-02 Hetero Research Foundation Novel betulinic substituted amide derivatives as hiv inhibitors
WO2017021922A1 (en) 2015-08-05 2017-02-09 Hetero Research Foundation Novel substituted amides of triterpene derivatives as hiv inhibitors
US10669305B2 (en) 2015-10-13 2020-06-02 Hetero Labs Limited C-3 novel triterpenone with C-28 urea derivatives as HIV inhibitors
WO2017115329A1 (en) 2015-12-30 2017-07-06 Hetero Research Foundation C-3 novel triterpenone derivatives as hiv inhibitors
WO2017149518A1 (en) 2016-03-04 2017-09-08 Hetero Labs Limited C-3 novel triterpene with c-17 amine derivatives as hiv inhibitors
WO2018025247A1 (en) 2016-08-05 2018-02-08 Hetero Labs Limited C-3 novel triterpenone with c-28 diamide derivatives as hiv inhibitors
WO2018029602A1 (en) 2016-08-08 2018-02-15 Hetero Labs Limited C-3 novel triterpenone with c-28 heterocycle derivatives as hiv inhibitors
WO2018029604A1 (en) 2016-08-08 2018-02-15 Hetero Labs Limited C-3 novel triterpenone with c-17 reverse amide derivatives as hiv inhibitors
WO2018029610A1 (en) 2016-08-09 2018-02-15 Hetero Labs Limited C-3 novel triterpenone with c-17 n-amide derivatives as hiv inhibitors
US20180097839A1 (en) 2016-10-01 2018-04-05 Neeraj S. Upasani Systems, apparatuses, and methods for platform security
WO2018069857A1 (en) 2016-10-12 2018-04-19 Hetero Labs Limited C-3 novel triterpenone with c-17 reverse amide heterocycle derivatives as hiv inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057420A2 (en) * 2006-11-03 2008-05-15 Panacos Pharmaceuticals, Inc. Extended triterpene derivatives
WO2009082819A1 (en) * 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel lupane derivatives

Also Published As

Publication number Publication date
ES2780649T3 (en) 2020-08-26
MX2017010297A (en) 2018-11-12
US11034718B2 (en) 2021-06-15
WO2016178092A8 (en) 2017-09-21
US20180215780A1 (en) 2018-08-02
CL2017002034A1 (en) 2018-04-27
PE20171433A1 (en) 2017-09-26
CA2975359A1 (en) 2016-11-10
EP3256483B1 (en) 2019-12-11
CN107428797A (en) 2017-12-01
SG11201706189PA (en) 2017-08-30
PH12017550077A1 (en) 2018-02-12
EA033264B1 (en) 2019-09-30
DK3256483T3 (en) 2020-03-23
EP3256483A2 (en) 2017-12-20
IL253844A0 (en) 2017-09-28
BR112017017109A2 (en) 2018-04-03
US10533035B2 (en) 2020-01-14
JP2018505216A (en) 2018-02-22
US20170008921A1 (en) 2017-01-12
US20200087342A1 (en) 2020-03-19
CO2017008765A2 (en) 2017-11-10
KR20170110143A (en) 2017-10-10
AU2016258274A1 (en) 2017-09-07
CU20170102A7 (en) 2018-01-10
WO2016178092A2 (en) 2016-11-10
AU2016258274B2 (en) 2019-12-05
EA201791807A1 (en) 2018-01-31
MA40886B1 (en) 2020-03-31
ZA201705253B (en) 2020-01-29
CU24476B1 (en) 2020-03-04

Similar Documents

Publication Publication Date Title
WO2016178092A3 (en) C-3 novel triterpenone with c-28 reverse amide derivatives as hiv inhibitors
PH12018500259A1 (en) Muscarinic agonists
WO2015101958A3 (en) Inhibitors of glutaminase
MD20170016A2 (en) Aminopyrimidinyl compounds as JAK inhibitors
MX2012000565A (en) Lupeol-type triterpene derivatives as antivirals.
WO2016105564A8 (en) Quinazoline derivatives used to treat hiv
WO2016172134A3 (en) Novel compounds
MX2020011449A (en) Oxysterols and methods of use thereof.
MX2016011632A (en) Azaspiro derivatives as trpm8 antagonists.
MX2020010674A (en) Muscarinic receptor agonists.
EP4316591A3 (en) Oxysterols and methods of use thereof
EA201270800A1 (en) C-28 AMIDES OF MODIFIED DERIVATIVES OF C-3 BETULINIC ACID AS AN HIV INHIBITORS INHIBITORS
WO2013160810A3 (en) Novel betulinic acid derivatives as hiv inhibitors
EP4356969A3 (en) Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
EA201591406A1 (en) C-19 MODIFIED TRITERPENOIDS WITH INHIBITOR ACTIVITY OF HIV MATURATION
GEP20186938B (en) Indolizine derivatives as phoshoinositide 3-kinases inhibitors
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
CY1121063T1 (en) INHIBITORS OF ALDOSTERONE COMPOSITION
WO2015198263A3 (en) Novel betulinic proline substituted derivatives as hiv inhibitors
MX2017013099A (en) Methods for the treatment of inflammatory disorders.
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
PH12017500558A1 (en) 4'-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus rna replication
AU2017215529A8 (en) C-3 and C-17 modified triterpenoids as HIV-1 inhibitors
WO2015001541A3 (en) Pharmaceutical film composition
WO2016147099A3 (en) C-3 novel triterpenone with c-28 amide derivatives as hiv inhibitors

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2975359

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 11201706189P

Country of ref document: SG

REEP Request for entry into the european phase

Ref document number: 2016784277

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 253844

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2017559931

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12017550077

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 001370-2017

Country of ref document: PE

Ref document number: 15549678

Country of ref document: US

Ref document number: MX/A/2017/010297

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017017109

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: NC2017/0008765

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 20177024961

Country of ref document: KR

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16784277

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2016258274

Country of ref document: AU

Date of ref document: 20160209

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201708935

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 201791807

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 112017017109

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170809